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1.1 Prevalence of Pain 
 
Pain is part of the human experience. Pain has been defined as an unpleasant sensory and 
emotional experience associated with actual or potential tissue damage, or described in terms of 
such damage (International Association for the Study of Pain (IASP), 2011). Acute and chronic 
pain affects large numbers of individuals around the world, including the U.S. In 2011, over 1.5 
billion people worldwide were burdened by chronic pain (Global Industry Analysts, Inc., 2011), 
including 100 million U.S. adults, more than the number affected by heart disease, diabetes, and 
cancer combined (Institute of Medicine, 2011).  The effects of pain are extremely expensive not 
only in terms of health care costs, but also in rehabilitation and lost worker productivity. Pain 
also places a huge financial and emotional burden on patients and their families. The total 
national annual economic cost associated with pain ranges from $560 billion to $635 billion. 
This estimate includes the incremental cost of health care ($261-300 billion) and the cost of lost 
productivity ($297-336 billion) attributable to pain (Institute of Medicine, 2011).    
For many patients, the treatment of pain is inadequate. In 2006, the National Center for 
Health Statistics reported that over one-quarter of Americans (26%) age 20 years and over 
reported that they have had a problem with pain that persisted for more than 24 hours in duration. 
Another 2006 study conducted by the American Pain Foundation evaluated chronic pain in 
patients who had been treated by a physician and were using an opioid for treatment. They 
reported that 51% of patients felt that they had little or no control over their pain and 60% 
experienced pain one of more times daily, despite being treated. These episodes of pain were 
severely impacting their quality of life. 59% reported an impact of their overall enjoyment of 
life, 77% felt depressed, 70% had trouble concentrating, 74% said their energy level was 
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decreased, and 86% reported an inability to sleep well. Furthermore, in 2009, Asmundson and 
Katz discovered that patients suffering from chronic pain were more prone to experience 
psychological problems including depression, panic disorders, compulsive behavior, anxiety 
abnormalities, and stress-related disorders like post-traumatic stress disorder (PTSD). A first step 
in addressing the worldwide burden of pain is understanding the underlying mechanisms that 
lead to the perception of pain, and how these may be altered in pathological pain states. This 
understanding will facilitate the proper development and use of pain treatments.  
 
1.2 Pain Processing  
Pain, like all other somatic sensory modalities, serves an important protective function. 
Pain alerts individuals to injuries and leads them to seek out treatment. Not being able to feel 
pain can be dangerous because severe injuries often go unnoticed and can lead to permanent 
tissue damage. Congenital insensitivity to pain (CIP) is a condition that inhibits the ability to feel 
physical pain. CIP is caused by a mutation in the sodium channel gene SCN9A that leads to the 
loss of function of NaV1.7, a voltage gated sodium channel type IX alpha subunit (Drenth & 
Waxman, 2007). NaV1.7 sodium channels are found in nociceptors, the neurons responsible for 
the transmission of pain signals to the spinal cord and brain (Wang et al., 2011). CIP is an 
extremely rare disorder, and as of 2012 only an estimated 20 cases had been reported in the 
scientific literature (Genetics Home Reference).  The case of Miss C exemplifies what can 
happen when people are born with insensitivity to pain (Melzack & Wall, 1988). As a child, 
Miss C suffered from many childhood injuries that resulted from her inability to experience pain, 
including burning herself on a radiator and biting her tongue while eating.  This lack of 
awareness of pain led to an accumulation of bruises, wounds, broken bones, and other health 
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issues that went undetected. As an adult, she developed joint problems as a result of a lack of 
discomfort from staying in one position for too long. She died at age 29 from infections that 
probably would have been prevented if she could have perceived pain and was alerted to injury 
risk (Melzack & Wall, 1988).  
Pain differs from nociception. Nociception refers to the neurophysiologic manifestations 
generated by noxious stimuli, while pain is the perception of an aversive stimulus, which 
requires abstraction and the elaboration of sensory impulses (Millan, 1999).  Pain is not the 
direct expression of a sensory event, but rather the product of elaborate processing by the brain 
of multiple incoming signals. The perception of pain is subjective and influenced by many 
factors. An identical sensory stimulus can elicit different responses in distinct individuals as well 
as in the same individual under different conditions (Kandel et al., 2013).  
Pain comes in two major forms, acute and chronic. Acute pain is defined by a limited 
period of time and disappears upon the resolution of the pathological process. Chronic pain is 
pain that persists for an extended period of time and is associated with chronic pathological 
processes (Merskey & Bogduk, 1994).  
The experience of pain begins with the activation of nociceptors, free nerve endings of 
primary sensory neurons that respond to various forms of tissue damage, to bodily processes that 
signal damage, such as inflammation, and to stimuli that have the potential to harm tissues 
(including extreme temperatures below 5 C and above 45 C) (Kandel et al., 2013; Purves et al., 
2012). Because nociceptive axons terminate in unspecialized endings, they are categorized by the 
properties of their nerve fibers. Aδ fibers are lightly myelinated that respond to intense 
mechanical or to mechanothermal stimuli. C fibers are unmyelinated fibers that respond to 
thermal, mechanical, and noxious chemical stimuli. There are three main classes of nociceptors: 
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thermal, mechanical, and polymodal. Thermal nociceptors are activated by extreme temperatures 
and are the peripheral endings of small diameter Aδ axons that conduct potentials at speeds of 5 
to 30 m/s. Mechanical nociceptors are activated by intense pressure on the skin and are also the 
nerve endings of Aδ axons. Polymodal nociceptors are activated by high intensity mechanical, 
chemical, or thermal stimuli and are the endings of small-diameter, unmyelinated C axons that 
conduct action potentials at speeds less that 1m/s (Supplemental Image 1). The receptor fields of 
nociceptors are relatively large and are widely distributed in skin and deep tissues, meaning they 
are often coactivated (Kandel et al., 2013; Purves et al., 2012).  
The activation of nociceptors eventually leads to the perception of pain. There are two 
major categories of pain perception: a sharp first pain and a more delayed and longer lasting 
second pain. Aδ fibers propagate specific information, with high intensity and short latency. 
They are responsible for the quick, sharp first pain that triggers a withdrawal response. C fibers 
propagate more slowly. These slow potentials induce aching and sometimes a burning pain, 
referred to as second pain (Kandel et al., 2013; Purves et al., 2012). 
Nociceptors are the free nerve endings of dorsal root ganglia and trigeminal ganglia 
(Kandel et al., 2013; Purves et al., 2012). When these axons reach the dorsal horn, they branch 
into ascending and descending collaterals, creating the dorsolateral tract of Lissauer. Axons in 
this tract run up or down for one or two spinal cord segments before innervating the dorsal horn 
in several of Rexed’s laminae. These dorsal root ganglia carrying nociceptive information 
innervate laminae I, II, and V. Laminae I and V contain projection neurons whose axons travel to 
the brainstem and thalamus. C fibers terminate exclusively in laminae I and II, while Aδ fibers 
synapse in layers I and V. Laminae I and II are the outermost layers of the dorsal horn of the 
spinal cord and are known as the marginal zone (layer I) and substantia gelatinosa (layer II). 
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Many neurons in lamina I respond to noxious stimuli carried by Aδ and C fibers, and are known 
as nociception-specific neurons. A second group of lamina I neurons receives input from C fibers 
that are selectively activated by extreme cold. Other classes of lamina I neurons respond to both 
noxious and innocuous mechanical stimulation and are called wide-dynamic-range neurons. 
Lamina II, the substantia gelatinosa, is filled with both excitatory and inhibitory interneurons, 
some of which respond selectively to nociceptive inputs, while others respond to both 
nocicpeptive and innocuous stimuli. Lamina V contains neurons that respond to a variety of 
noxious stimuli. These neurons receive direct inputs from Aδ fibers, as well as from non-
nociceptive Aβ fibers, which communicate crude touch. The dendrites of these neurons also 
extend into laminae IV, III, and II and are innervated by C fibers in lamina II. In summary, 
neurons in lamina I receive direct input from Aδ fibers and direct and indirect (via interneurons 
of lamina II) from C fibers. Lamina V neurons receive low threshold input from non-nociceptive 
Aβ fibers of mechanoreceptors and inputs from nociceptive Aδ and C fibers (Supplemental 
Image 2). The axons of the second order neurons in laminae I and V cross the midline and 
ascend into the brainstem and thalamus in the anterolateral fascicle of the contralateral spinal 
cord. These fibers form anterolateral tract (Kandel et al., 2013; Purves et al., 2012).  
 
1.3 Pain Pathways 
There are six major ascending pathways that convey nociceptive information: The 
spinothalamic, spinoreticular, spinomesencephalic, spinoparabrachial, spinocervical, and 
spinohypothalamic tracts, but this thesis will focus on the spinothalamic and the 
spinoparabrachioamygdaloid (SPA) division of the spinoparabrachial tract (Almeida et al., 2004; 
Kandel et al., 2013). The spinothalamic tract is the most prominent ascending nociceptive 
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pathway (Supplemental Image 3). It includes the axons of nociceptive-specific, thermosensitive, 
and wide-dynamic-range neurons in laminae I and V, which carry noxious potentials that are 
related to pain, temperature, touch, and itching. These axons cross the midline and travel up the 
anterolateral white matter of the contralateral spinal cord. The fibers of the spinothalamic tract 
project to the thalamus where they form synapses in the thalamic ventral posterior nucleus 
(VPN). Neurons of the VPN project to the primary and secondary somatosensory cortex (S1, 
S2), where the perception of pain begins to be processed. The sensory-discriminative aspects of 
pain: the location, intensity, and quality of the noxious stimuli are thought to depend on 
information relayed through the spinothalamic tract into S1 and S2 (Kandel et al., 2013; 
Kenshalo & Insensee, 1983; Purves et al., 2012).  
Other divisions of the pain system are responsible for the affective-motivational aspects: 
the unpleasant feeling, fear, anxiety, and the autonomic activation that accompany exposure to 
noxious stimuli. Targets of these systems include the superior colliculus, the reticular formation, 
the hypothalamus, the periaqueductal gray matter, the septal nucleus, the anterior cingulate 
cortex, the insula, and the amygdala (Purves et al., 2012; Willis & Westlund, 1997). Evidence 
from functional imaging studies has shown that different brain regions mediate the sensory-
discriminative and affective-motivational aspects of pain. Painful stimuli activate both the 
primary somatosensory cortex and anterior cingulate cortex. Using hypnotic suggestion to 
selectively increase or decrease unpleasantness or intensity of pain, it was discovered that 
changes in unpleasantness were accompanied by changes in the activity of neurons in the 
anterior cingulate cortex (Rainville, 1997), while changes in intensity were highly correlated 
with changes in the activity of neurons in the somatosensory cortex (Hofbauer, 2001). The SPA 
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pathway has been implicated as an important pathway for the affective-motivational aspects of 
pain.  
 
1.4 The CeA in Pain Processing  
Over the last 20 years, the amygdala, especially its central nucleus (CeA), has emerged as 
a key element of the pain matrix. The amygdala is centrally located to integrate the many 
ascending and descending signals to modulate both the emotional and sensory aspects of pain. It 
possesses connections that influence the descending pain control systems and is also connected 
to other brain regions involved in emotional, affective, and cognitive functions. The CeA 
receives nociceptive information from the brainstem and receives highly processed descending 
polymodal nociceptive information from the cerebral cortex and the thalamus. This descending 
information is conveyed to the basolateral amygdala (BLA), which then projects to the CeA. The 
CeA in turn projects to other brain nuclei. The CeA efferents include those that travel with anti-
nocieption hypothalamic-periaqueductal grey projections that dampen pain (Veinante et al., 
2013).  The most prominent ascending pathway carrying nociceptive information to the CeA is 
the SPA pathway. In the SPA pathway, primary Aδ and C fibers terminate in laminae I and V, 
where second order neurons project to the parabrachial nuclei (PBn) (Todd, 2010) (Supplemental 
Image 4).  The PBn collects nociceptive information, including both mechanical and thermal 
nociceptive signals, and relays the information in a highly organized topographical manner to the 
lateral capsular division of the CeA (CeLC). This ascending pathway does not require the 
conveyance of information through the BLA. In addition, spinal neurons in the deep dorsal horn 
form monosynaptic connections with amygdala neurons and may provide sensory, including 
nociceptive, input to the amygdala (Burstein & Potrebic, 1993).  
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The CeA is the output nucleus for major amygdala functions. It modulates various 
systems involved with emotional response through widespread, reciprocal connections with the 
forebrain and brainstem, including the bed nucleus of the stria terminalis (BNST), frontal cortical 
areas, hippocampus, septal nuclei, lateral hypothalamus, parabrachial area, solitary tract nucleus 
and brain stem areas involved in endogenous pain control (as reviewed by Neugebauer & Li, 
2002). 
The role of the CeA in pain processing and the modulation of pain behavior has been 
highly investigated. Nociceptive stimuli have been shown to increase several markers of CeA 
activation (Rouwette et al., 2012). In vivo electrophysiological studies have shown that chronic 
pain and noxious stimuli increase spontaneous and evoked CeA neuronal activity (Bernard et al., 
1992; Neugebauer & Li, 2002; Neugebauer & Li, 2003).  Neugebauer and Li (2002) discovered 
that mechanical and thermal cutaneous nociceptive stimulation as well as joint and muscular 
deep tissue nociception provoked excitability in neurons of the CeA. Further studies 
demonstrated that most of these neurons were located in the CeLC, while few neurons in the 
central (CeL) and medial (CeM) division of the CeA responded to nociceptive stimulation. This 
gave rise to the name “nociceptive amygdala” to define the CeLC (Neugebauer et al., 2004). 
In vivo electrophysiological studies have also revealed that noxious stimuli and chronic 
pain increase synaptic transmission at PBn-CeA and BLA-CeA synapses (Ikeda et al., 2007; 
Neugebauer et al., 2003) Neugebauer et al. (2003) noted that CeA neurons of arthritic rats 
developed an increased excitability compared with control CeA neurons. Synaptic plasticity was 
accompanied by upregulation of presynaptic group I metabotropic glutamate receptors (mGluR1 
and mGluR5) and increased presynaptic mGluR1 function, demonstrating a physiological 
response to pain at the level of the synapse. Studies have also shown that visceral, inflammatory, 
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and chronic pain can induce c-Fos expression in the CeA. Specifically, intraperitol or esophageal 
acetic acid injection (Nakagawa et al., 2003; Suwanprathes, 2003), colorectal distension (Traub 
et al., 1996) and experimental cystitis (Bon et al., 1998) were discovered to induce c-fos 
expression in the CeA.  
Human brain neuroimaging studies have implicated the amygdala in pain. Painful stimuli 
increase blood oxygen level dependent  (BOLD) signals in the amygdala (Bornhövd, 2002). 
Furthermore, Bornhövd and colleagues (2002) found that repeated thermal nociceptive 
stimulations of increasing intensity led to an activation of the amygdala that was correlated with 
the pain perception rating. Behavioral studies in animals have also revealed that the CeA plays a 
role in pain perception. Electrical stimulation of the amygdala elicited vocalizations 
accompanied by emotional responses in monkeys (Jurgens et al., 1967). Lesions or temporary 
inactivation of the CeA decreased tonic pain responses (Manning, 1998) as well as emotional 
pain reactions, without altering normal behavior or baseline nociceptive responses (as reviewed 
by Neugebauer & Li, 2002). Chronic pain was also shown to induce anxiety in mice with 
concomitant changes in opiodergic function in the amygdala (Narita et al., 2006). The amygdala, 
specifically its CeA, appears to modulate the behavioral and emotional responses to pain.  
 
1.5 PACAP and Pain 
Pituitary adenylate cyclase activating polypeptide (PACAP) is a well-studied, widely 
expressed neural and endocrine pleiotropic peptide. PACAP has been found to exert pleiotropic 
effects, participating in control of neurotransmitter release, vasodilation, bronchodilation, 
stimulation of cell proliferation and/or differentiation, promotion of neuronal survival, sensory 
and autonomic signaling, hippocampal learning and memory processes, and stress-related 
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behavioral responses (as reviewed by Vaudry et al., 2009). PACAP was originally isolated from 
the hypothalamus based on its ability to stimulate anterior pituitary adenylyl cyclase activity 
(Miyata et al., 1989). PACAP arises from a prohormone that can be cleaved into two formations, 
the bioactive α-amidated PACAP 38 or PACAP 27 (Miyata et al., 1990). PACAP38 appears to 
be the more abundant version, with 10-fold to 100-fold more PACAP38 in most tissues including 
the central nervous system (CNS) (Arimura et al., 1991; Miyata et al., 1990). PACAP binds to 
three G-protein receptors; to PAC1 selectively and to VPAC1 and VPAC2, which bind PACAP 
and VIP with equal affinities (Harmar et al., 2012). 
PACAP systems have been shown to be dysregulated in emotional-related processes. 
There is a PACAP single-nucleotide polymorphism (SNP) associated with PTSD (Ressler et al., 
2011), a SNP associated with schizophrenia (Hashimoto et al., 2007) and a SNP associated with 
major depression (Hashimoto et al., 2010). The SNPs can occur on the PAC1 receptor gene or on 
the PACAP gene itself. Furthermore, our laboratory recently demonstrated that the expression of 
PACAP and its PAC1 receptor were upregulated in specific limbic regions by chronic stress and 
that PACAP infusion into the BNST was anxiogenic (Hammack et al., 2009).  
PACAP has also been shown to alter pain responses at various levels of the nervous 
system. Studies have demonstrated that intrathecal injections of PACAP induced mechanical 
hyperalgesia in mice (Ohsawa et al., 2002), intrathecal injections of PACAP produced 
hyperalgesia in tail-flick assays (Narita et al., 1996), and PACAP knockout animals did not 
display neuropathic mechanical sensitivity after spinal nerve transection (Mabuchi et al., 2004; 
Sándor, 2010). These results suggest an important involvement of PACAP in pain and 
nociception. 
Using the knowledge that the SPA pathway projects from the PBn to the CeLC , 
  
11
PACAPergic fibers project from the PBn (Bernard et al., 1993; as reviewed by Hammack & 
May, 2014), and PACAP can alter pain, our laboratory investigated the presence of PACAP in 
the CeLC. Missig et al. (2014) identified PACAP immunoreactivity in fiber elements of the 
CeLC and used anterograde tracing to demonstrate that the CeLC PACAP immunoreactivity 
represented sensory fiber projects from the lateral PBn (LPBn). In addition, Missig et al. (2014) 
provided evidence that the LPBn was the PACAP source of both the CeLC as well as the BNST 
through excitotic lesion studies. Excitotic lesions of the LPBn led to a significant decrease in 
PACAP immunoreactivity in both the CeLC and the BNST (Missig et al., 2014). Evidence that 
PACAP cells in PBn project to the CeA and that the CeA contains PACAP suggests that PACAP 
release may be critical for the perception of pain.  
With the discovery of PACAP within the CeA and the knowledge that the CeA plays a 
central role in the emotional process of pain, we investigated the effects of PACAP on pain 
processing.  In this study, we examined the effects of CeA PACAP infusion on thermal and 
mechanical nociception and found that bilateral PACAP infusions into the CeA reduced 
nociceptive thresholds on Hangreaves thermal sensitivity tests, but not on von Frey mechanical 
sensitivity assessments.  
2.0 Methods 
2.1 Animals 
16 Adult (250-350g), male, Sprague-Dawley rats were obtained from Charles River 
Laboratories (Wilmington, MA) and were habituated in their home cages in the animal facility 
for at least one week before experimentation. Rats were single-housed, maintained on a 12 h 
light/dark cycle (lights on at 07:00 h), and food and water were available ad libitum. All 





2.2.1 Mechanical Apparatus 
Von Frey Filaments: A set of 20 Semmes-Weinstein monofilaments (Stoelting, Wood 
Dale, IL) were used with a target force between 2 and 26 grams. However, filaments were not 
used that had a target force greater than 10% of the rat’s body weight as they could raise the 
hindpaw in absence of a paw withdrawal.  
2.2.2 Thermal Apparatus 
Hargreave’s apparatus (Plantar Analgesia Meter, IITC Life Science Inc., Woodland Hills, 
CA) is a heating apparatus that measures response to infrared heat stimulus, applied to the 
plantar surface. A guide light was used to allow the experimenter to target the hindpaw. A beam 
of focused radiant light (4x6 mm, set to 25% active intensity) from the apparatus beneath the 
glass of the testing chamber was delivered to the plantar surface of the paw. An automatic cut-off 
timer set at 30 seconds was built into the system to prevent tissue damage. 
2.2.3 Testing Chamber 
The testing chamber was a clear, acrylic chamber placed on top of a wire mesh for the 
mechanical threshold testing and a glass platform for thermal threshold testing with an internal 
heating element that heated to 30°C.  (IITC Life Science Inc., Woodland Hills, CA).  
2.3 Surgical Procedure 
To implant indwelling cannulae, rats were anesthetized with isoflurane vapor (1.5 - 
3.5%), and secured in a stereotaxic apparatus (David Kopf Instruments, Tujunga, CA) with 
“blunt” earbars. A midline incision was made and the skull was exposed and cleaned. Four 
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screws were then inserted to provide skullcap stability. Two stainless steel cannulae (22 GA, 
PlasticsOne, Roanoke, VA) were lowered into the CeA, using the following coordinates from 
bregma in mm, AP = -2.6, ML = + 4.5, and DV = - 7.2 at a 0 degree angle. Once in place, the 
cannulae were held in place using dental cement (Hammack et al., 2009).  
2.4 Post-Operative Procedure 
Once awake, rats were returned to their home cages for one week of post-surgery 
recovery, during which the animals received post-operative analgesia (Carprofen 5mg/kg) and 
were routinely wrapped in a towel to habituate handling. The animals were also observed and 
weighed daily. After the post-operative week the rats were habituated to the testing chamber for 
20 minutes a day for 4 days with a fan to generate ambient noise. Following habituation, rats 
were then assessed for baseline withdrawal thresholds to both thermal and mechanical stimuli for 
two days.  
2.5 Testing Procedures 
Following baseline withdrawal assessment, rats were loosely restrained in a towel and the 
CeA was infused with sterile saline (control) or PACAP (1µg in 0.5µl each side) over two 
minutes (.25 µl/min) (Harvard Apparatus, Holliston, MA), through an internal cannula that 
projected 1mm from the guide cannulae (Hammack et al., 2009). The infusion needle was left in 
place for a minute following infusion. Animal body weights were determined before and 24 
hours after infusions. 
2.5.1 Mechanical Sensitivity Testing 
Following infusion, rats were placed into the testing chamber and mechanical sensitivity 
was tested using von Frey Fiber testing at 30 minutes, 2 hours, 24 hours and 48 hours after 
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infusion. On the day of testing rats were placed in the testing chamber on top of a metal mesh 
and habituated for 10 minutes before von Frey filament testing. Following habitation, von Frey 
filament testing occurred. In ascending diameter thickness, each filament was applied to the 
lateral plantar surface of the hindpaw until bent at 30 degrees for 5-7 seconds. A positive 
response was defined as a swift withdrawal of the hindpaw. The mechanical threshold was 
defined as the force of the smallest filament that resulted in 3 out of 5 hindpaw withdrawals to 
the von Frey hair stimulation. If a negative response occurred the next von Frey hair was tested. 
Thresholds from both the right and left hindpaws were measured and the average mechanical 
threshold from the left and right hindpaw was recorded. One animal was excluded due to ceiling 
effect on baseline. 
2.5.2 Thermal Sensitivity Testing 
Latency to hindpaw withdrawal to thermal stimuli was measured at 1, 4, 24, and 72 hours 
after infusion. On the day of testing rats were placed in the testing chamber on the glass platform 
and habituated for 10 minutes before von Frey filament testing Rats were place in the testing 
chamber and a Hargreave’s apparatus (Plantar Analgesia Meter, IITC Life Science Inc., 
Woodland Hills, CA) was used to measure withdrawal latency to a thermal stimulus. A focused 
radiant beam of light (4x6 mm, set to 25% active intensity) was placed on the hindpaw. The 
point at which the hindpaw was withdrawn or the hindpaw was licked, the heat source was 
immediately terminated and the reaction time was recorded. For measurements to thermal 
stimuli, each time point was the average of 3 paw withdrawal latencies from both the left and 
right hindpaw separated by 5 minute intertrial intervals. The PACAP and vehicle treatment 
groups exhibited similar average baseline latency scores (PACAP, 11.6±0.7s; vehicle, 
11.1±0.6s).  
  
2.6 Analyses of Data 
Statistics were calculated using a repeated mea
to PACAP treatment. The data was analyzed using GraphPad PRISM. Bonferroni’s multiple 
comparisons tests were used to compare treatment effects at all time points and adjusted P values 
were calculated. 
2.7 Cannula Verification  
To verify cannula placements in the CeA, rats were anesthetized and underwent 
transcardial perfusion with 4% paraformaldehyde. Brains were then removed, fixed in 4% 
paraformaldehyde, equilibrated in a 30% sucrose solution, 
compound, frozen, and sectioned on a cryostat at 50µm. The sections were then mounted on 
slides and stained with a Cresyl Violet solution. Cannula verifications were conducted under a 
light microscope. Only data from correct CeA cannula placements 
 
3.1 Histological Verification  
 
 Only data from correct CeA cannula 
placements were included in the analysis (Image 1). 





sures 2-way ANOVA comparing Vehicle 
embedded in Tissue-Tek OCT 
were included in the results.
3.0 Results 





3.2 Mechanical and Thermal Sensitivity 
 










Figure 1 displays the mechanical threshold of hindpaw withdrawal and Figure 2 (see 
below) displays the latency of hindpaw withdrawal to a thermal stimulus for e
time. Treatments groups were assigned to have matching baseline scores prior to testing, 
(Mechanical: PACAP: 16.4 g, Vehicle:14.6g, Thermal: PACAP: 11.7s, Vehicle: 11.6s). Statistics 
were calculated using a 2-way ANOVA comparing Vehicle to PACAP treatment. 
Infusion of PACAP into the CeA had no effect on mechanical threshold. No significant 
difference in threshold was observed after the infusion of PACAP into the CeA (F(5, 60)=0.412, 
p>0.05). There was a significant main effect of time point (F(5,60)=12.28, p<0.0001), with a 
gradual increase in mechanical sensitivity over time
hoc analyses revealed a significant difference between B1 and all post infusion time points and a 









. Mean +/- SEM. 
  
significant difference between B2 and 2 hours and B2 and 24 hours. 
main effect of PACAP treatment (F(1,12)=0.9726, p>0.05) and no s
(F(5,60)= .412, p>0.05). 
Figure 2: CeA PACAP infusion increased thermal sensitivity. B1 and B2 are baseline values
 
Infusion of PACAP into the CeA had a significant effect on paw withdrawal latency
thermal stimulus. There was a significant main effect of time
no significant main effect of treatment (F(1,12)=0.9726, p>0.05). There was a significant 
interaction between treatment and time
post-hoc tests revealed that PACAP significantly reduced 
diminished by 4 hours. Withdrawal responses remained 
and had returned to near baseline values.
thermal hyperalgesia at one hour after infusion that dissipated by 4 hours, but had no effect on 
mechanical sensitivity.  
 There was no significant 
ignificant interaction 
. Mean +/
 point (F(5,60)=3.358, p<0.05), but 
 point (F(5,60)=4.021, p< 0.05). Bonferonni corrected 
withdrawal latency at 1 hour that 
non-significant at 24 hours and 72 hours 
 These results suggest that CeA PACAP infusion led to 
17
- SEM. 




CeA PACAP infusion had no effect on mechanical sensitivity, but led to thermal 
hyperalgesia that dissipated after 4 hours. We discovered a reduction in paw withdrawal latency 
in response to thermal stimuli at 1 hour among rats that had received CeA PACAP infusion. 
The CeA is a brain region of converging pathways involving pain, stress, and emotion 
and plays an important role in mediating the emotional elements of pain. It modulates both 
ascending and descending nociceptive signals. The CeLC is innervated by LPBn neurons that 
form part of the SPA pathway, one of the major pathways that convey nociceptive information to 
the brain and that is particularly important for modulating the emotional components of pain 
(Veinante et al., 2013). Previous studies in our laboratory demonstrated that PACAP is present in 
the CeLC and that a major source of PACAP to the CeLC is the LPBn (Missig et al, 2014), The 
presence of PACAP within the parabrachioamygdaloid pathway suggests that PACAP may be a 
critical mediator in emotional aspects of pain. To facilitate the effects of PACAP in the CeLC, 
our studies demonstrated the CeA PACAP infusions increased noxious stimulus responses in 
thermal reactivity tests.   
CeA PACAP infusion had no effect on mechanical sensitivity, but led to thermal 
hyperalgesia that began to dissipate after 4 hours. It was hypothesized that infusion of PACAP 
into the CeA would decrease the mechanical and thermal thresholds, leading to a reduction in 
paw withdrawal latency in response to thermal and mechanical stimulation. Because of its 
potential role in mediating the emotional components of pain, we expected that the microinfusion 
of PACAP into the CeA might potentiate pain responses. This hypothesis was based on the 
prediction that PACAP released by the PBn is potentiating CeA synapses as part of the PBn-CeA 
nociceptive pathway. Previous research had shown that other neuropeptides, including calcitonin 
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gene-related peptide (CGRP)  receptor ligands (Han et al., 2010) and mGluRs ligands (Crock et 
al., 2012), play this role in the amygdala and when injected into the CeA increased mechanical 
sensitivity.  
Although mechanical threshold in PACAP-treated animals appeared lower compared to 
vehicle controls after 30 minutes, analyses revealed a trend rather than statistical difference. 
There was no significant difference between PACAP treated animals and controls at any time 
point. Rather, there was only a main effect of time, with a gradual decrease in mechanical 
threshold with repeated testing over time. The simplest explanation for this result is animals’ 
sensitization to the von Frey hairs over time, independent of PACAP.  
There was, however, a reduction in paw withdrawal latency in response to thermal 
stimuli at 1 hour among rats that had received CeA PACAP infusion. Thermal and mechanical 
pain are transduced by separate fibers and mechanisms, these distinctions may have contributed 
to the observed differences in the efficacy of PACAP. The PBn demonstrates greater responses 
to thermal stimuli than to mechanical stimuli (Bernard et al., 1996) and it is possible that the 
transfer of these signals to the CeLC resulted in smaller PACAP-mediated mechanical responses. 
The variance in results between mechanical and thermal nociception may also be explained by a 
difference in the intensity of the stimulus.  From the results we can speculate that the von Frey 
hairs were bothersome rather than painful, which explains why both the PACAP infused rats and 
controls became more sensitive to mechanical stimulation from 30 minutes to 24 hours. A-Delta 
nociceptive fibers respond to both dangerously intense mechanical or to mechanothermal stimuli, 
whereas C fibers respond to thermal, mechanical, and chemical stimuli (Purves et al., 2012).  In 
this case, the von Frey hairs may not have activated nociceptors, but rather may have activated 
rapidly adapting mechanotranducers (A-Beta fibers). Hargreaves Test, on the other hand, 
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allowed for intense thermal stimulation of the hindpaw. Therefore, due to either the intensity or 
modality of the stimulus Hargreaves Test was more likely to activate nociceptors than von Frey 
testing. If PACAP in the CeA alters pain circuits involving nocicepetive fibers and pathways 
then we would only expect to see a change in thresholds among stimuli that are transmitted via 
nociceptors. 
Furthermore, even if von Frey hairs do activate nociceptors, neuropeptides, including 
PACAP, require high frequency stimulation to be released. The differential release of small-
molecule transmitters and neuropeptides is probably based on the distribution of Ca2+ and 
vesicles in the presynaptic terminal. Small-molecule transmitters are found in vesicles docked to 
the presynaptic membrane before Ca2+ entry whereas vesicles containing neuropeptides are 
further from the presynaptic membrane. At low frequency stimulation, the increase in Ca2+ 
appears to remain close to the Ca2+ channels limiting release to small-molecules because their 
vesicles neighbor these channels. Higher levels of stimulation increase the concentration of Ca2+ 
throughout the presynaptic terminal, leading to the release of neuropeptides (Purves et al., 2012). 
Given that PACAP is a neuropeptide it is likely that PACAP is only released when nociceptive 
stimuli are of high intensity.  
It is possible that infused PACAP synergizes with endogenous PACAP that is only 
released in response to high intensity stimulation, such as thermal stimulation. If endogenous 
PACAP is only released in response to Hargreaves test and not in response to von Frey hair 
testing and endogenous and infused PACAP synergize, then one would only expect to see a 
change in hindpaw withdrawal in response to thermal stimulation. This could explain why only 
thermal and not mechanical stimulation led to a change in hindpaw withdrawal. 
In congruence with this idea, Stroth et al. (2013) argued that PACAP is the main 
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neurotransmitter during periods of high firing rates. In their study, they demonstrated that 
catecholamine (CA) secretion evoked by direct high-frequency stimulation of the splanchnic 
nerve is abated from male PACAP-deficient mice and found that PACAP is both necessary and 
sufficient for CA secretion ex vivo during stimulation protocols that mimic stress. This may 
explain why thermal stimulation, but not mechanical stimulation led to a shift in latency of 
hindpaw withdrawal. It is possible that Hargreaves test reached the high frequency necessary for 
PACAP to become the main neurotransmitter in the implicated SPA pathway whereas von Frey 
testing did not. Therefore, a significant decrease in hindpaw withdrawal latency would only be 
expected in response to thermal stimulation.  
Afferents to the CeA do not only release PACAP, but also contain glutamate and contain 
other neuropeptides including CGRP (Missig et al., 2014). Therefore, glutamate may be released 
at low levels of stimulation, while PACAP may only be released alongside glutamate in the 
presence of a very salient stimulation. PACAP, then, would augment the effects of glutamate. In 
concordance with this idea, Cho et al. (2012) demonstrated that PACAP increases synaptic 
excitability in the CeA. Specifically, they found that PACAP augmented glutamatergic input in 
the CeA, leading to an increase in excitatory postsynaptic potentials (EPSPs). Enhancement of 
synaptic transmission by PACAP would explain PACAP’s ability to alter pain processing in the 
CeA.   
 PACAP receptors may also play a role in modulation of emotional aspects of pain in the 
CeA. Following our research, Missig et al. (2014) found that the thermal and mechanical 
sensitivity responses were recapitulated with the PAC1 receptor-specific agonist maxadilan. 
These results implicated specific activation of the PAC1 receptor in these mechanical and 
thermal responses.  
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The signal transduction of PACAP is important to understanding the effects that PACAP 
has on the emotional aspects of pain. PACAP can be coupled to multiple G-protein systems (as 
reviewed by Hammack & May, 2014). One of the downstream mediators of central pain 
processing is phosphorylated extracellular signal-regulated kinase (pERK) (Polgar et al., 2007). 
ERK phosphorylation is observed in the CeA in acid induced muscle pain (Cheng et al., 2011) 
and after interplantar formalin (Carrasquillo & Gereau, 2007). ERK has been demonstrated to be 
a downstream molecule for PACAP (May et al., 2014) and our laboratory recently demonstrated 
that pERK increases as a result of PACAP stimulation (Missig et al., unpublished) Furthermore, 
Missig and colleagues (unpublished) recently demonstrated that inhibition of ERK blocked the 
induction of thermal sensitivity by PACAP.  PACAP appears to be activating plasticity pathways 
that involve ERK. 
Carrasquillo and Gereau (2007) demonstrated that activation of ERK in the amygdala 
was both necessary for and sufficient to provoke long-lasting peripheral tactile hypersensitivity. 
In contrast to our results, inhibiting ERK in the CeA decreased mechanical, but not thermal 
hypersensitivity. Similarly, the direct pharmacological activation of ERK induced mechanical, 
but not thermal hypersensitivity, in the absence of peripheral inflammation. These results 
demonstrated that molecular pathways in the amygdala might modulate thermal and mechanical 
hypersensitivity in distinct ways.  
One explanation for these conflicting results is that the exact neurons being activated in 
our study and the Carasquillo and Gereau study may be distinct. Our study only activated a 
subset of neurons that contain PACAP receptors (mostly receiving input from the PBn), which 
may have resulted in distinct hypersensitivities. Also, there may be different pathways activated 
by PACAP in addition to ERK that affect sensitivity. PACAP signals through Gs/cAMP and 
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Gq/phospholipase C(PLC) pathways, which have a variety of downstream targets including ERK 
(as reviewed by Hammack & May, 2014). These other downstream targets and their interactions 
may also be important in generating a specific sensitivity response. Similarly, the mechanism by 
which ERK is activated could be important. Unique to PACAP/PAC1 receptor signaling, the 
PAC1 receptor is able to signal through internalization from the cell membrane into the cytosol, 
forming a signaling endosome complex that activates ERK (May et al., 2014; Merriam et al., 
2013). This unique receptor signaling mechanism of PACAP/PAC1 could lead to distinct ERK 
activation.  
Although this study found no change in mechanical sensitivity, the possibility still exists 
that CeA PACAP infusion results in mechanical hyperalgesia to stronger stimuli. To evaluate 
this, additional behavioral tests should be performed to measure responses to more intense 
mechanical stimuli. One possibility is a Randall-Selitto test, a test that applies increasing 
amounts of pressure to a rat’s hindpaw. Another possibility is that PACAP in the amygdala 
might selectively alter sensitivity to thermal and not mechanical stimuli.  This could be examined 
by using other forms of mechanical and thermal stimulation to see if PACAP effects are specific 
to modality.  
 Pain is a universal experience. Acute and chronic pain affect large numbers of individuals 
around the world and cost economies billions of dollars. For many patients, treatment of pain is 
inadequate; over 1.5 billion people worldwide report suffering from chronic pain (Global 
Industry Analysts, Inc., 2011). The first step in addressing the worldwide burden of pain is 
discovering the underlying neurological mechanisms that lead to the perception of pain so that 
appropriate treatments can be developed. Understanding the role of PACAP in the modulation of 
pain will further our comprehension of pain as a whole and the intersection between pain and 
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